AstraZeneca’s Imfinzi Gets Pass From FDA Advisors But Future Perioperative Drugs Don’t

 
• By Sarah Karlin-Smith
black and white image of doctor with floating lungs above doctor's hands.
The ODAC discussion may have saved AstraZeneca's Imfinizi from a complete response letter. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers